Completed Studies Summary

Economic Evaluation of ZAMPACT TB diagnostic strategies using modern technologies-Gene Expert and LED-florescent microscope. It was a sub-study of The Zambia Project for Actively Curing Tuberculosis (ZAMPACT) study. The aim of ZAMPACT was to detect and successfully treat more cases of accurately diagnosed TB through health systems and community systems strengthening and to determine, through operational research, the efficiency, treatment monitoring system and cost effectiveness of two geneXpert algorithms for TB diagnosis.

The economic evaluation took a provider’s perspective to estimate the cost-effectiveness ratios of the ZAMPACT TB diagnostic algorithms. Cost analysis of OraQuick® ADVANCE Rapid HIV-1/2 antibody test and two blood-based rapid HIV antibody tests. The study was a sub-study of Field comparison of OraQuick® ADVANCE Rapid HIV-1/2 antibody test and two blood-based rapid HIV antibody tests in Zambia. The outcome paper was published in BMC Infectious Diseases in 2012.

Economic evaluation of eye services in Zambia. The study was done in between December 2011 and June 2012. We worked in collaboration with the London School of Hygiene and Tropical Medicine (LSHTM). We also had a Master’s studentship to do a project module. The outcome paper just go published in the Cost Effectiveness and Resource Allocation in 2014.


Economic Evaluation of ZAMSTAR: This study was conducted as part of Zambia-South Africa TB and AIDS Reduction (ZAMSTAR) study, a community randomized trial. The trial was conducted in 24 communities, 16 inZambia and 8 in the Western Capeprovince of South Africa. The trial was conducted between July 2006 and June 2009 (36 months). The primary outcome for the study is the prevalence of tuberculosis after three years of intervention, measured through surveys of a random sample of adults (aged > 15 years) from each community. The economic evaluation to calculate the costs and cost-effectiveness of implementing ZAMSTAR interventions from the provider’s perspective. A draft of the outcome papers underway.

Economic Evaluation of of TB cultures using solid (Lowenstein-Jensen, LJ) and liquid (the Mycobacteria Growth Indicator Tube, MGIT) media in Zambia. The study aimed to assess the cost-effectiveness of the two TB diagnostic technologies in a poor resource setting. The outcome paper was published in International Journal of Tuberculosis and Lung Diseases in 2008.



  • Impact of HIV on the clinical course of TB (EU)
  • Effect of TB preventive therapy amongst HIV-positive people (DFID & WHO)
  • Patterns of transmission of TB using molecular techniques (EU, Optimus & Beit)
  • TB control in an urban area with high TB/HIV prevalence (diagnostic delay, adherence to treatment, diagnostic process, role of private practitioners and home based care) (EU)
  • Feasibility of TB preventive therapy (Wellcome & DFID)
  • ProTEST initiative – integrated care for people living with HIV – one of the core elements of the new WHO/UNAIDS framework for TB/HIV control (DFID & WHO)
  • Household counselling for TB patients and their families (Wellcome & DFID)
  • Understanding women’s and community views about MTCT of HIV (Glaxo-Wellcome)
  • National surveys on TB drug resistance (WHO & GFATM)
  • Understanding TB and HIV-related stigma and resulting discrimination (USAID, UNICEF)
  • Addressing obstacles to effective TB diagnosis within hospital settings (DFID)
  • Barriers to uptake of TB/HIV interventions (BMGF)
  • Evaluating new TB diagnostic tools (DFID, FIND)
  • Converging impact of TB, food insecurity and HIV (IFPRI, RENEWAL)
  • Economic impact of TB (DFID & EU)
  • Providing a package of continued care to clients of the current MTCT intervention (WHO)
  • Reducing TB prevalence at the community level using innovative approaches (BMGF)
  • Access to ART in the national roll-out (DFID)
  • Implementation of new TB diagnostic test (Gene Xpert) (WHO)
  • Household level intervention on combined TB and HIV care (ZAMSTAR) (BMGF)
  • PopART trial – impact of a package of HIV prevention interventions on community-level HIV incidence.